. 2006 Sep;80(17):8411–8421. doi: 10.1128/JVI.00369-06

TABLE 5.

Antiviral activity of HIV-1 strains mutated at glycosylation sites in gp120

Compound	EC₅₀ (μM) for wild type	Antiviral activity (fold resistance) for virus isolate^a:
Compound	EC₅₀ (μM) for wild type	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18
HHA	0.006	6.3	19	1.9	17	55	28	0.8	83	83	15	133	110	39	75	67	262	919	490
GNA	0.010	5.2	8.3	1.9	10	40	27	0.3	31	33	6.1	39	44	117	72	78	99	926	581
CA	0.024	10	11	8.1	6.7	27	13	1.9	42	45	32	39	32	45	85	58	140	233	133
LOA		5.8	3.8	5.0	5.5			1.3	32	33	10	102	158	80	43	16	109	228	246
CV-N	0.003	1.5	7.4	0.68	4.2	7.9	6.8	0.3	43	37	1.3	57	50	83	2.9	6.3	5.1	29	11

1, PRMA-8-1; 2, PRMA-30-1; 3, PRMA-8-2; 4, PRMA-30-2; 5, PRMA-30-3; 6, PRMA-30-4; 7, UDA-20; 8, UDA-25-1; 9, UDA-50-1; 10, UDA-15-2; 11, UDA-50-2; 12, UDA-100-2; 13, UDA-200-2; 14, GNA-2.1; 15, HHA-2.2; 16, HHA-500CS; 17, HHA-500SN; 18, GNA-500CS.